CD8A and neoplasm: Furthermore, based on a preclinical PDX model with tumor‐specific CD8+ T cell transfer, we confirmed the synergistic effect of the combination of EHBP1L1 inhibition and PD‐1 blockade compared to PD‐1 blockade monotherapy.